AP983A - Freeze-dried composition of bone morphogenetic protein human MP52. - Google Patents

Freeze-dried composition of bone morphogenetic protein human MP52. Download PDF

Info

Publication number: AP983A
Authority: AP; ARIPO
Prior art keywords: bone morphogenetic; morphogenetic factor; factor human; mannitol; composition
Prior art date: 1997-01-30

Application number

APAP/P/1999/001602A

Other languages

English (en)

Other versions

AP9901602A0 (en

Inventor

Hideki Ichikawa

Mitsuko Inagaki

Original Assignee

Biopharm Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-01-30

Filing date

1998-01-29

Publication date

2001-07-16

1998-01-29 Application filed by Biopharm Gmbh filed Critical Biopharm Gmbh

1999-09-30 Publication of AP9901602A0 publication Critical patent/AP9901602A0/xx

2001-07-16 Application granted granted Critical

2001-07-16 Publication of AP983A publication Critical patent/AP983A/en

Links

108010007726 Bone Morphogenetic Proteins Proteins 0.000 title claims abstract description 37
102000007350 Bone Morphogenetic Proteins Human genes 0.000 title claims abstract description 37
239000000203 mixture Substances 0.000 title claims abstract description 37
101100472152 Trypanosoma brucei brucei (strain 927/4 GUTat10.1) REL1 gene Proteins 0.000 title claims abstract description 36
229940112869 bone morphogenetic protein Drugs 0.000 title 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 27
235000010355 mannitol Nutrition 0.000 claims abstract description 25
229930195725 Mannitol Natural products 0.000 claims abstract description 23
239000000594 mannitol Substances 0.000 claims abstract description 23
238000002156 mixing Methods 0.000 claims abstract description 4
239000000243 solution Substances 0.000 claims description 11
238000002360 preparation method Methods 0.000 claims description 7
238000010353 genetic engineering Methods 0.000 claims description 4
238000000034 method Methods 0.000 claims description 2
239000011259 mixed solution Substances 0.000 claims 1
238000004108 freeze drying Methods 0.000 abstract description 8
238000004040 coloring Methods 0.000 abstract description 2
206010003694 Atrophy Diseases 0.000 abstract 1
230000037444 atrophy Effects 0.000 abstract 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
239000000047 product Substances 0.000 description 7
230000011164 ossification Effects 0.000 description 6
238000001962 electrophoresis Methods 0.000 description 4
238000012360 testing method Methods 0.000 description 4
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
239000000825 pharmaceutical preparation Substances 0.000 description 3
229940127557 pharmaceutical product Drugs 0.000 description 3
238000013112 stability test Methods 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
150000005846 sugar alcohols Polymers 0.000 description 2
108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 1
102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
230000010354 integration Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000001002 morphogenetic effect Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
239000004474 valine Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Zoology (AREA)
Orthopedic Medicine & Surgery (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

APAP/P/1999/001602A 1997-01-30 1998-01-29 Freeze-dried composition of bone morphogenetic protein human MP52. AP983A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP1634997		1997-01-30
PCT/JP1998/000371 WO1998033514A1 (en)	1997-01-30	1998-01-29	Freeze-dried composition of bone morphogenetic protein human mp52

Publications (2)

Publication Number	Publication Date
AP9901602A0 AP9901602A0 (en)	1999-09-30
AP983A true AP983A (en)	2001-07-16

Family

ID=11913900

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
APAP/P/1999/001602A AP983A (en)	1997-01-30	1998-01-29	Freeze-dried composition of bone morphogenetic protein human MP52.

Country Status (22)

Country	Link
EP (1)	EP0972520B9 (pl)
JP (1)	JP4209948B2 (pl)
KR (1)	KR100548107B1 (pl)
CN (1)	CN1152712C (pl)
AP (1)	AP983A (pl)
AT (1)	ATE302021T1 (pl)
AU (1)	AU737595B2 (pl)
BR (1)	BR9807537B1 (pl)
CA (1)	CA2278546C (pl)
DE (1)	DE69831223T9 (pl)
DK (1)	DK0972520T3 (pl)
EA (1)	EA001579B1 (pl)
ES (1)	ES2244043T3 (pl)
HU (1)	HU226554B1 (pl)
IL (2)	IL130967A0 (pl)
NO (1)	NO322334B1 (pl)
NZ (1)	NZ336509A (pl)
PL (1)	PL189381B1 (pl)
RS (1)	RS49691B (pl)
SI (1)	SI0972520T1 (pl)
TR (1)	TR199901832T2 (pl)
WO (1)	WO1998033514A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4388602B2 (ja) †	1997-02-07	2009-12-24	ストライカーコーポレイション	マトリクスを含まない骨形成デバイス、移植片、およびその使用方法
WO2003030873A1 (en) *	2001-10-09	2003-04-17	Cellfactors Plc	Therapeutic biological product and method for formation of new vascularised bone
BR0214275A (pt)	2001-11-19	2004-09-21	Scil Technology Gmbh	Dispositivo tendo propriedades osteocondutora e osteoindutora
WO2004024199A1 (en)	2002-09-10	2004-03-25	Scil Technology Gmbh	Metal implant coated under reduced oxygen concentration with osteoinductive protein
EP1651272A1 (en) *	2003-08-05	2006-05-03	Fuji Photo Film B.V.	Use of recombinant or synthetic gelatin as a stabiliser in vaccines
EP1685160A1 (en) *	2003-11-10	2006-08-02	Arriva-Prometic Inc.	Dry recombinant human alpha 1-antitrypsin formulation
PL1737734T3 (pl)	2004-03-10	2011-02-28	Scil Tech Gmbh	Powlekane implanty, ich wytwarzanie i zastosowanie
US20160344677A1 (en)	2015-05-22	2016-11-24	Microsoft Technology Licensing, Llc	Unified messaging platform for providing interactive semantic objects
US10360287B2 (en)	2015-05-22	2019-07-23	Microsoft Technology Licensing, Llc	Unified messaging platform and interface for providing user callouts

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1996033215A1 (en) *	1995-04-19	1996-10-24	Hoechst Pharmaceuticals & Chemicals K.K.	Novel protein and process for producing the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0080879B1 (en) *	1981-11-28	1986-10-01	Sunstar Kabushiki Kaisha	Pharmaceutical composition containing interferon in stable state
US5037644A (en) *	1986-10-27	1991-08-06	Cetus Corporation	Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
KR0145278B1 (ko) *	1991-06-21	1998-07-15	브루스 엠. 에이센	골형성원 단백질 약제
JP2966592B2 (ja) *	1991-07-20	1999-10-25	萩原義秀	安定化されたヒトモノクローナル抗体製剤
CZ287715B6 (en) *	1992-02-12	2001-01-17	Bioph Biotech Entw Pharm Gmbh	DNA sequence, recombinant DNA molecule containing thereof, process for preparing protein from the group of TGF-beta substances, pharmaceutical preparation containing such protein, antibody or fragment thereof and its use
CA2093836A1 (en) *	1992-04-24	1993-10-25	Wayne Gombotz	Biodegradable tgf-.beta. delivery system for bone regeneration
DE4239877C1 (de) *	1992-11-27	1994-03-17	Boehringer Ingelheim Int	Stabilisierte Superoxid-Dismutase (SOD)-Zusammensetzung
AU707796B2 (en) *	1995-03-21	1999-07-22	Merck Serono Sa	HCG liquid formulations

1998
- 1998-01-29 PL PL98334852A patent/PL189381B1/pl not_active IP Right Cessation
- 1998-01-29 EP EP98901044A patent/EP0972520B9/en not_active Expired - Lifetime
- 1998-01-29 AT AT98901044T patent/ATE302021T1/de active
- 1998-01-29 TR TR1999/01832T patent/TR199901832T2/xx unknown
- 1998-01-29 IL IL13096798A patent/IL130967A0/xx active IP Right Grant
- 1998-01-29 DK DK98901044T patent/DK0972520T3/da active
- 1998-01-29 EA EA199900694A patent/EA001579B1/ru not_active IP Right Cessation
- 1998-01-29 SI SI9830798T patent/SI0972520T1/sl unknown
- 1998-01-29 NZ NZ336509A patent/NZ336509A/xx not_active IP Right Cessation
- 1998-01-29 WO PCT/JP1998/000371 patent/WO1998033514A1/ja not_active Ceased
- 1998-01-29 JP JP53271798A patent/JP4209948B2/ja not_active Expired - Fee Related
- 1998-01-29 DE DE69831223T patent/DE69831223T9/de active Active
- 1998-01-29 HU HU0002386A patent/HU226554B1/hu not_active IP Right Cessation
- 1998-01-29 CN CNB988019841A patent/CN1152712C/zh not_active Expired - Fee Related
- 1998-01-29 CA CA002278546A patent/CA2278546C/en not_active Expired - Fee Related
- 1998-01-29 AU AU56791/98A patent/AU737595B2/en not_active Ceased
- 1998-01-29 RS YUP-349/99A patent/RS49691B/sr unknown
- 1998-01-29 ES ES98901044T patent/ES2244043T3/es not_active Expired - Lifetime
- 1998-01-29 KR KR1019997006833A patent/KR100548107B1/ko not_active Expired - Fee Related
- 1998-01-29 AP APAP/P/1999/001602A patent/AP983A/en active
- 1998-01-29 BR BRPI9807537-3A patent/BR9807537B1/pt not_active IP Right Cessation
1999
- 1999-07-15 IL IL130967A patent/IL130967A/en not_active IP Right Cessation
- 1999-07-29 NO NO19993702A patent/NO322334B1/no not_active IP Right Cessation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1996033215A1 (en) *	1995-04-19	1996-10-24	Hoechst Pharmaceuticals & Chemicals K.K.	Novel protein and process for producing the same

Also Published As

Publication number	Publication date
EA199900694A1 (ru)	2000-04-24
CN1152712C (zh)	2004-06-09
HUP0002386A3 (en)	2002-09-30
NO993702D0 (no)	1999-07-29
ATE302021T1 (de)	2005-09-15
RS49691B (sr)	2007-12-31
CN1244127A (zh)	2000-02-09
SI0972520T1 (sl)	2006-02-28
HUP0002386A2 (hu)	2000-11-28
PL189381B1 (pl)	2005-07-29
PL334852A1 (en)	2000-03-27
IL130967A0 (en)	2001-01-28
BR9807537B1 (pt)	2009-01-13
HU226554B1 (en)	2009-03-30
BR9807537A (pt)	2000-03-21
ES2244043T3 (es)	2005-12-01
EP0972520B9 (en)	2006-03-22
DE69831223T2 (de)	2006-02-16
DE69831223T9 (de)	2006-12-07
YU34999A (sh)	2002-08-12
AU5679198A (en)	1998-08-25
AP9901602A0 (en)	1999-09-30
EP0972520A4 (en)	2002-11-05
EA001579B1 (ru)	2001-06-25
KR100548107B1 (ko)	2006-02-02
NO993702L (no)	1999-09-29
KR20000070586A (ko)	2000-11-25
JP4209948B2 (ja)	2009-01-14
IL130967A (en)	2006-12-10
DE69831223D1 (de)	2005-09-22
AU737595B2 (en)	2001-08-23
NO322334B1 (no)	2006-09-18
CA2278546A1 (en)	1998-08-06
WO1998033514A1 (en)	1998-08-06
DK0972520T3 (da)	2005-12-19
TR199901832T2 (xx)	1999-12-21
EP0972520B1 (en)	2005-08-17
NZ336509A (en)	2001-03-30
CA2278546C (en)	2008-04-01
EP0972520A1 (en)	2000-01-19

Publication	Publication Date	Title
AU627174B2 (en)	1992-08-20	Human growth hormone formulation
US5919443A (en)	1999-07-06	Stable lyophilized pharmaceutical preparations of G-CSF
KR100942399B1 (ko)	2010-02-17	Ｅｇｆ 수용체에 대한 항체를 함유하는 동결건조된 제제
EP1174148A1 (en)	2002-01-23	Parenteral medicinal composition containing humanized monoclonal antibody fragment and method for stabilizing the same
JP2007045841A (ja)	2007-02-22	ヒト成長ホルモン水性製剤
HU202761B (en)	1991-04-29	Process for producing stabilized erythropoietin compositions
AU738413B2 (en)	2001-09-20	Human growth hormone-containing aqueous pharmaceutical composition
JPH08505610A (ja)	1996-06-18	貯蔵安定性なｇ−ｃｓｆの水性薬理製剤
US20220133633A1 (en)	2022-05-05	Pharmaceutical taci-fc fusion protein formulation
AP983A (en)	2001-07-16	Freeze-dried composition of bone morphogenetic protein human MP52.
KR100377967B1 (ko)	2003-06-12	Hcg액상조성물
KR20040018458A (ko)	2004-03-03	Ｃｅｔｕｘｉｍａｂ 및 폴리옥시에틸렌 소르비탄 지방산에스테르를 포함하는 액형 제제
US20040132653A1 (en)	2004-07-08	Lyophilized composition of bone morphogenetic factor human MP52
JPWO1998033514A1 (ja)	2000-07-11	骨誘導因子ヒトｍｐ５２凍結乾燥組成物
CA1289071C (en)	1991-09-17	Pharmaceutical compositions for parenteral use containing a calcitonin as the active ingredient
MXPA99006784A (en)	2000-07-01	Freeze-dried composition of bone morphogenetic protein human mp52
RU2160605C2 (ru)	2000-12-20	Жидкие композиции, содержащие человеческий хорионический гонадотропин (hcg)
JPH01246226A (ja)	1989-10-02	安定な修飾アスパラギナーゼ含有組成物
UA50811C2 (uk)	2002-11-15	Ліофілізована композиція морфогенетичного фактора кістки, спосіб одержання ліофілізованої композиції морфогенетичного фактора кістки
JP2005232177A (ja)	2005-09-02	Ｈｇｈ含有医薬組成物
US20160095904A1 (en)	2016-04-07	Stabilized liquid formulation
JPS62149623A (ja)	1987-07-03	安定なｇｒｆ製剤
CA2215936A1 (en)	1996-09-26	Hcg liquid formulations